News | Intra-Aortic Balloon Pumps (IABP) | June 06, 2018

FDA Class 1 Recall of Maquet Datascope IABPs Due to Fluid Seepage

Maquet Datascope Corp. is recalling the CardioSave Hybrid Intra-aortic Balloon Pump (IABP).

The touchscreen Maquet Datascope CardioSave Hybrid Intra-aortic Balloon Pump (IABP) system console.

June 6, 2018 — Maquet Datascope Corp. said it is recalling the CardioSave Hybrid Intra-aortic Balloon Pump (IABP) due to fluid ingress that may affect device operation, interrupt or delay therapy. 

The U.S. Food and Drug Administration (FDA) issued a safety alert today that stated a design issue in the IABP can allow fluid (such as saline) to seep into the device. The fluid can cause corrosion of internal components such as the electronic circuit boards. The FDA said this can lead to device malfunction like sudden stops, which can cause a delay or interruption in therapy. The FDA said device failure may result in immediate and serious adverse health consequences, including death. 

The recall includes CardioSave Hybrid IABP part numbers: 0998-00-0800-XX, 0998-UC-0800-XX and cart 0997-00-1179 (excluding 0998-00-0800-83, 0998-UC-0800-83 & 0998-00-0800-75). The FDA said all lots are affected by this recall. 

The manufacturing dates include Dec 12, 2011 through April 25, 2018. The distribution dates were between March 6, 2012 to April 26, 2018. 

The CardioSave IABP is a cardiac assist device used with patients undergoing cardiac and non-cardiac surgery, and to treat patients with acute coronary syndrome or complications from heart failure, the FDA stated. 

Recommendations for Users: 

   • Never place fluids on top of the unit

   • Ensure that the saline container and tubing do not hang directly over the IABP

   • In case of accidental spillage, to wipe clean immediately and have the unit serviced to ensure no hazard exists.

   • In case of an interruption in therapy, the letter instructed users to:

   • Transfer the patient to an alternative IABP   

   • If an alternative IABP is unavailable, manually inflate the IAB with air or helium and immediately aspirate repeat every five minutes until either an alternate IABP is available or alternatively (i.e., if an alternative IABP is not available in a reasonable amount of time) the intra-aortic balloon catheter should be removed from the patient.

 

The FDA said affected customers will be contacted by Maquet Datascope Corp. to schedule on-site service of the IABP by a Maquet Datascope Corp. sales or service representative. The company anticipates having the protective top cover available by late June 2018.

U.S. customers wanting more information about this recall can contact Maquet Datascope Corp.’s Technical Support Department at 1-888-627-8383 (press option 3), Monday through Friday, between 8 a.m. and 6 p.m. Eastern Standard Time.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program at www.fda.gov/MedWatch/report.

Link to FDA Safety Alerts in 2018
 

Related Content

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Overlay Init